FogPharma, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently available medicines using its Helicon peptide platform, and ARTBIO Inc., a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), have partnered to co-develop Helicon-enabled ARTs (HEARTs) to transform outcomes for patients with multiple types of cancer.
 
ARTBIO and FogPharma will co-develop novel HEARTs against multiple targets, leveraging FogPharma’s Helicon platform of tunable stabilized α-helical peptides and ARTBIO’s AlphaDirect platform for the development of ARTs using the isotope, 212Pb. ARTs with 212Pb have the ideal clinical profile due to a short half-life that delivers maximal energy into tumors with high stability and the ability to image with SPECT/CT. The synergy of these two powerful platforms offers promising potential to create next-generation ARTs with properties ideal for precise delivery to tumors.
 
“We are thrilled to begin our collaboration with ARTBIO, wherein we extend the use of our Helicons to bind extracellular proteins and use our Helicons to finely tune distribution and elimination properties, paving the way for a new safe and effective category of targeted radioligand therapy,” stated Mathai Mammen, M.D., Ph.D., CEO of FogPharma. “Our aim is to revolutionize outcomes for cancer patients in critical need.”
 
“This collaboration with FogPharma enables ARTBIO to advance next-generation therapeutics specifically designed to treat solid tumors,” said Emanuele Ostuni, Ph.D., CEO of ARTBIO. “FogPharma has a shared vision of radically changing the current treatment paradigms for cancers, and together we will fuse science, technology, and collective passion to improve patient outcomes.”
 
The partners will contribute equally to the collaboration across research, development and commercialization phases. Additional financial terms are undisclosed.